Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methoxyamine with Chemo-Radiation for NSCLC
NCT02535325Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2015
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methoxyamine hydrochloride in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Sep 2015; status: completed.
02
Drugs
methoxyamine hydrochloride
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02535325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535325.